SCHEMBL20914307

SCHEMBL20914307

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nc2ccc(N)cc2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.39
▸ POLB P06746 4/20 0.39
▸ ALDH1A1 P00352 6/20 0.38
▸ MAPT P10636 5/20 0.38
▸ HPGD P15428 5/20 0.38
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ GLA P06280 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ ARF6 P62330 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ P2RY6 Q15077 1/20 0.36
▸ CASP1 P29466 1/20 0.35
▸ GPR119 Q8TDV5 5/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913958 0.89 KDM4E (0.41) KDM4EPOLBALDH1A1MAPTHPGD
SCHEMBL20913987 0.84 SMN1; SMN2 (0.46) KDM4EPOLBALDH1A1MAPTHPGD
SCHEMBL20914267 0.84 KDM4E (0.38) KDM4EPOLBALDH1A1MAPTHPGD
SCHEMBL20914015 0.84 POLB (0.37) KDM4EPOLBALDH1A1MAPTMEN1
SCHEMBL20914095 0.83 ALDH1A1 (0.40) KDM4EPOLBALDH1A1MAPTHPGD
SCHEMBL20914419 0.82 MECP2 (0.45) KDM4EPOLBALDH1A1HPGDNPC1
SCHEMBL20914314 0.82 NPC1 (0.43) KDM4EPOLBALDH1A1MAPTHPGD
SCHEMBL20914411 0.81 POLB (0.39) KDM4EPOLBALDH1A1MEN1KMT2A
SCHEMBL20914166 0.81 POLB (0.40) KDM4EPOLBALDH1A1HPGDMEN1
SCHEMBL20914004 0.80 POLB (0.39) KDM4EPOLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KDM4E 1922/4885POLB 4311/4885ALDH1A1 1246/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KDM4E 1922/4885POLB 4311/4885ALDH1A1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback